Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery

Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concen...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul, Mahasweta, Lau, Raymond
Other Authors: School of Chemical and Biomedical Engineering
Format: Article
Language:English
Published: 2022
Subjects:
Online Access:https://hdl.handle.net/10356/160960
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-160960
record_format dspace
spelling sg-ntu-dr.10356-1609602022-08-08T08:30:03Z Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery Paul, Mahasweta Lau, Raymond School of Chemical and Biomedical Engineering Engineering::Bioengineering Particle Characterization Inhalation Drug Delivery Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concentrations for longer periods and the ability to bypass the blood brain barrier. This review aims to highlight and summarize the recent advances made in the development of Levodopa particle formulations in terms of its characteristics, production techniques, choice of carrier materials, as well as pharmacokinetics and pharmacodynamics the formulations. 2022-08-08T08:30:03Z 2022-08-08T08:30:03Z 2020 Journal Article Paul, M. & Lau, R. (2020). Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery. Advanced Powder Technology, 31(6), 2357-2365. https://dx.doi.org/10.1016/j.apt.2020.03.028 0921-8831 https://hdl.handle.net/10356/160960 10.1016/j.apt.2020.03.028 2-s2.0-85083305054 6 31 2357 2365 en Advanced Powder Technology © 2020 The Society of Powder Technology Japan. All rights reserved.
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Engineering::Bioengineering
Particle Characterization
Inhalation Drug Delivery
spellingShingle Engineering::Bioengineering
Particle Characterization
Inhalation Drug Delivery
Paul, Mahasweta
Lau, Raymond
Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery
description Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concentrations for longer periods and the ability to bypass the blood brain barrier. This review aims to highlight and summarize the recent advances made in the development of Levodopa particle formulations in terms of its characteristics, production techniques, choice of carrier materials, as well as pharmacokinetics and pharmacodynamics the formulations.
author2 School of Chemical and Biomedical Engineering
author_facet School of Chemical and Biomedical Engineering
Paul, Mahasweta
Lau, Raymond
format Article
author Paul, Mahasweta
Lau, Raymond
author_sort Paul, Mahasweta
title Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery
title_short Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery
title_full Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery
title_fullStr Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery
title_full_unstemmed Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery
title_sort potentials and challenges of levodopa particle formulation for treatment of parkinson's disease through intranasal and pulmonary delivery
publishDate 2022
url https://hdl.handle.net/10356/160960
_version_ 1743119573381545984